|
Oct 1
|
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society
|
|
May 10
|
Edgewise Therapeutics Inc (EWTX) Reports First Quarter 2024 Financial Results
|
|
May 10
|
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
|
|
May 9
|
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
|
May 7
|
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
|
|
May 7
|
Edgewise Therapeutics doses first subject in HCM drug trial
|
|
May 6
|
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
|
|
Apr 23
|
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
|
|
Apr 15
|
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
|
|
Mar 28
|
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
|
|
Mar 27
|
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
|
|
Mar 5
|
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
|
|
Feb 26
|
Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know
|
|
Feb 22
|
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
|
|
Feb 21
|
13 Best Booming Stocks to Buy Right Now
|
|
Jan 9
|
Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 25
|
We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth
|
|
Dec 19
|
Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
|
|
Dec 18
|
Edgewise Therapeutics Launches First of Its Kind Educational Website Dedicated to the Becker Muscular Dystrophy Community
|
|
Nov 30
|
Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA
|